Radiofrequency Ablation for Renal Tumours: A Retrospective Cohort From a Tertiary Hospital in Australia

2021 ◽  
Author(s):  
Mohammed Al-Zubaidi ◽  
Kennia Lotter ◽  
Martin Marshall ◽  
Mikhail Lozinskiy
Keyword(s):  
Radiofrequency Ablation ◽  
Local Recurrence ◽  
Tumour Size ◽  
Tertiary Hospital ◽  
Complication Rates ◽  
Percutaneous Radiofrequency Ablation ◽  
Renal Tumours ◽  
Alternative Modality ◽  
Royal Perth Hospital

Abstract Purpose: This cohort aimed to evaluate the safety and efficacy outcomes of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) in a Western Australia tertiary hospital, Royal Perth Hospital (RPH), and potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities and local recurrence against existing benchmarks. Methods: We retrospectively analysed survival outcomes for patients with biopsy proven RCC treated by RFA at Royal Perth Hospital between 2009 and 2018. Complication data were gathered for all patients that underwent renal RFA along with 2- and 5-year recurrence-free (RFS) and compared the outcomes with data from previous studies. I confirm that all methods were carried out in accordance with relevant guidelines and regulations. Results: A total of 69 patients (73 procedures) were eligible for the study with biopsy-proven RCC had minimum 2-year follow-up. The RPH complication rate was 8.2 % (6/73) and local recurrence rate 10.9 % (8/73). Two-year RFS is 95.6% and Five-year RFS is 78.78% on a median 3.82-year follow-up (IQR 1.9-5.75). Conclusion: Radiofrequency ablation performed at our centre was found to be safe and effective with low complication rates and durable RFS in line with expectations from existing research. Our study demonstrated that radiofrequency ablation is an alternative modality of treatment for small renal tumours in patients unfit for surgical approach.

Effectiveness of Ultrasound-Guided Radiofrequency Ablation in the Treatment of 36 Renal Cell Carcinoma Tumours Compared with Published Results of Using Computed Tomography Guidance

2012 ◽  
Vol 63 (3_suppl) ◽  
pp. S23-S32 ◽  
Author(s):  
Kellie Davis ◽  
Ania Kielar ◽  
Katayoun Jafari
Keyword(s):  
Computed Tomography ◽  
Radiofrequency Ablation ◽  
Residual Disease ◽  
Tumour Size ◽  
Complication Rates ◽  
Ct Guided ◽  
Renal Lesions ◽  
Contrast Enhanced Ct ◽  
The Mean

This study aimed to analyse the outcomes of ultrasound (US) guided radiofrequency ablation (RFA) in patients with renal lesions and to compare our outcomes with published results of ablations carried out when using computed tomography (CT) guidance. This retrospective study evaluated RFA of 36 renal tumours in 32 patients (M = 21, F = 11). The mean patient age was 70 years (range, 39–89 years). Ablations were performed by using either multi-tined applicators or cooled and/or cluster applicators under US guidance. Applicator size varied from 2–5 cm, depending on the size of the index tumour. Conscious sedation was administered by an anesthetist. Follow-up imaging by using contrast-enhanced CT was performed 1, 3, 6, and 12 months after RFA, and yearly thereafter. The mean tumour follow-up time was 12 months (range, 1–35 months). The mean tumour size was 2.7 cm (range, 1–5 cm). Primary effectiveness was achieved in 31 cases (86.1%), with patients in 5 cases (11.1%) demonstrating residual disease. Three patients had repeated sessions, which were technically successful. The remaining 2 patients were not re-treated because of patient comorbidities. As a result, secondary effectiveness was achieved in 34 patients (94.4%). In 1 patient, a new lesion developed in the same kidney but remote from the 2 prior areas of treatment. Hydrodissection was performed in 3 patients (8.3%), manipulation or electrode repositioning in 11 patients (30.6%), and ureteric cooling in 1 patient (2.8%). Minor and major complications occurred in 3 (8.3%) and 3 (8.3%) patients, respectively. Correlation coefficients were calculated for distance from skin to tumour and risk of complication as well as compared with primary and secondary effectiveness. This study demonstrates that US-guided RFA is an effective treatment for renal lesions, with rates of effectiveness and complication rates comparable with published CT-guided RFA results.

Percutaneous radiofrequency ablation of renal tumours: 29-month mean follow-up results of 118 patients

2014 ◽  
Vol 20 (4) ◽  
pp. 219-228
Author(s):  
Albertas Ulys ◽  
Algirdas Žalimas ◽  
Rūta Merkytė ◽  
Sandra Selickaja ◽  
Mantas Trakymas
Keyword(s):  
Radiofrequency Ablation ◽  
Thermal Effects ◽  
Renal Tumors ◽  
Percutaneous Radiofrequency Ablation ◽  
Ultrasound Guided ◽  
Kidney Tumors ◽  
Renal Tumours ◽  
Invasive Method ◽  
The Mean

Background. Percutaneous radiofrequency ablation (RFA) is a minimally invasive method of treatment based on thermal effects. This retrospective study aimed to clarify percutaneous RFA of kidney tumors  –  performance, extremeness and 5-year survival in patients with small renal tumors in a single center. Materials and methods. Between September 2003 and December 2012, a total of 118 patients underwent percutaneous RFA of renal tumors. During more than 9  years period 144 RFA procedures were performed. Tumors were verified by biopsy. We used 3 RFA techniques: RFA under ultrasound control only (US), ultrasound guided RFA with CT navigation (US/CT) and ultrasound guided RFA with CT navigation, fiducial markers placed around the kidney tumor before the treatment (US/CT/FM). RFA electrodes were one and three. Patients were followed up regularly by CT with contrast enhancement. Results. The mean patient age was 68.72  years (range 28 to 86). The mean tumor size was 2.8 cm (range 1 to 5.4). The mean follow-up time was 29 months (1–111 months). Radical dependence on technical procedures: only US  39 (66.1%), US/CT 18 (94.7%), US/CT/FM 37 (92.5%), p = 0.001. Radical differences between using one and three electrodes: 39 (66.1%) and 55 (93.2%), p 

scholarly journals Radiofrequency Ablation versus Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Ali H. Hachem ◽  
Joseph E. Marine ◽  
Housam A. Tahboub ◽  
Sana Kamdar ◽  
Shaffi Kanjwal ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Radiofrequency Ablation ◽  
Meta Analysis ◽  
Fluoroscopy Time ◽  
Radiofrequency Energy ◽  
Cryoballoon Ablation ◽  
Complication Rates ◽  
Ablation Time ◽  
Significant Difference

Background. Pulmonary vein isolation is commonly performed using radiofrequency energy with cryoablation gaining acceptance. We performed a meta-analysis of randomized controlled trials which compared radiofrequency versus cryoablation for patients with atrial fibrillation. Methods. A systematic search strategy identified both published and unpublished articles from inception to November 10, 2016, in multiple databases. The primary outcomes for this meta-analysis were long-term freedom from atrial fibrillation at 12-month follow-up and overall postoperative complication rates. For all included studies, the methodological quality was assessed through the Cochrane Collaboration’s tool for risk of bias. Results. A total of 247 articles were identified with eight being included in this review as they satisfied the prespecified inclusion criteria. Overall, there was no significant difference in freedom from atrial fibrillation at ≥12-month follow-up between those receiving cryoballoon and radiofrequency ablation, respectively (OR = 0.98, CI = 0.67–1.43, I2 = 56%, p=0.90). Additionally, the secondary outcomes of duration of ablation, fluoroscopy time, and ablation time failed to reach significance. Cryoballoon ablation had significantly greater odds of postoperative phrenic nerve injury at 12-month follow-up. Conclusions. Our meta-analysis suggests that cryoballoon ablation provides comparable benefits with regard to freedom from atrial fibrillation at medium-term follow-up, fluoroscopy time, ablation time, operative duration, and overall complication rate in comparison to radiofrequency ablation.

Lessons from pathological analysis of recurrent early esophageal squamous cell neoplasia after complete endoscopic radiofrequency ablation

Endoscopy ◽  
2018 ◽  
Vol 50 (08) ◽  
pp. 743-750 ◽  
Author(s):  
Wen-Lun Wang ◽  
I-Wei Chang ◽  
Chien-Chuan Chen ◽  
Chi-Yang Chang ◽  
Cheng-Hao Tseng ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Local Recurrence ◽  
Endoscopic Resection ◽  
Squamous Cell ◽  
Complete Response ◽  
Primary Treatment ◽  
Long Term Follow Up ◽  
Endoscopic Radiofrequency Ablation ◽  
Lost To Follow Up

Abstract Background Endoscopic radiofrequency ablation (RFA) is a treatment option for early esophageal squamous cell neoplasia (ESCN); however, long-term follow-up studies are lacking. The risks of local recurrence and “buried cancer” are also uncertain. Methods Patients with flat-type ESCN who were treated with balloon-type ± focal-type RFA were consecutively enrolled. Follow-up endoscopy was performed at 1, 3, and 6 months, and then every 6 months thereafter. Endoscopic resection was performed for persistent and recurrent ESCN, and the histopathology of resected specimens was assessed. Results A total of 35 patients were treated with RFA, of whom 30 (86 %) achieved a complete response, three were lost to follow-up, and five (14 %) developed post-RFA stenosis. Two patients had persistent ESCN and received further endoscopic resection, in which the resected specimens all revealed superficial submucosal invasive cancer. Six of the 30 patients with successful RFA (20 %) developed a total of seven episodes of local recurrence (mean size 1.4 cm) during the follow-up period (mean 40.1 months), all of which were successfully resected endoscopically without adverse events. Histological analysis of the resected specimens revealed that six (86 %) had esophageal glandular ductal involvement, all of which extended deeper than the muscularis mucosae layer. Immunohistochemistry staining for P53 and Ki67 suggested a clonal relationship between the ductal involvement and epithelial cells. None of the tumors extended out of the ductal structure; no cases of cancer buried beneath the normal neosquamous epithelium were found. Conclusions Because ductal involvement is not uncommon and may be related to recurrence, the use of RFA should be conservative and may not be the preferred primary treatment for early ESCN.

Flow cytometric DNA analysis in conservatively treated renal tumours

1995 ◽  
Vol 62 (1_suppl) ◽  
pp. 141-143
Author(s):  
P. Beltrami ◽  
M. Lazzarotto ◽  
G. Giusti ◽  
C. Tallarigo ◽  
G. Malossini ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Dna Analysis ◽  
Tumour Size ◽  
Prognostic Significance ◽  
Dna Flow Cytometry ◽  
Additional Parameter ◽  
Flow Cytometric ◽  
Renal Tumours ◽  
Dna Histograms

— The DNA histograms of 21 conservatively resected renal tumours were studied using DNA flow cytometry. Five patients had an imperative and sixteen an elective indication for conservative resection of the renal tumour. On the basis of DNA histograms twelve aneuploid tumours were pointed out. A mean follow-up of 34.2 months was considered to see whether the ploidy would provide criteria with a prognostic significance, to be useful as an additional parameter. None of the twenty-one patients had local recurrence or distant metastasis: in our series the DNA analysis had no influence on the prognosis of this group of patients. The tumour size seems to be the only selective parameter for choosing renal-conserving surgery.

Comparison of cyanoacrylate embolization and radiofrequency ablation for the treatment of varicose veins

2018 ◽  
Vol 34 (4) ◽  
pp. 278-283 ◽  
Author(s):  
Gary K Yang ◽  
Marina Parapini ◽  
Joel Gagnon ◽  
Jerry C Chen
Keyword(s):  
Radiofrequency Ablation ◽  
Saphenous Vein ◽  
Great Saphenous Vein ◽  
Varicose Veins ◽  
Treatment Success ◽  
Vancouver General Hospital ◽  
Wound Complications ◽  
Complication Rates ◽  
Success Rates

Objective To review clinical outcomes of varicose vein patients treated with cyanoacrylate embolization and radiofrequency ablation at our institution. Methods A retrospective review of patients who underwent cyanoacrylate embolization and radiofrequency ablation during a three-year period. Patient records were reviewed to assess demographics, location and severity of disease, treatment details and outcome at short- and mid-term follow-ups. Outcome parameters included treatment success and complications. Results Between January 2014 and December 2016, 335 patients with 476 veins were treated with either cyanoacrylate embolization (n = 148) or radiofrequency ablation (n = 328) at the Vancouver General Hospital Vascular Surgery Vein Clinic. The average age of patients were 57 ± 1 years with the majority being female (78%) and an average BMI of 24.8 ± 0.5. CEAP classes were 2 (49%), 3 (26%), 4a (22%) and >4b (3%). Of the veins treated with cyanoacrylate embolization, the vein types were as follows: 76% were great saphenous vein, 16% were small saphenous vein, 5% were anterior accessory great saphenous vein and 1.4% were perforator veins. The vein types for radiofrequency ablation were 88%, 9%, 3% and 0%, respectively. The average amount of cyanoacrylate embolization delivered for great saphenous vein treatment was 1.8 ± 0.1 ml with a treatment length of 43 ± 1 cm. Subgroup comparison was done for great saphenous vein segments. Treatment success was 100% in cyanoacrylate embolization and 99% in radiofrequency ablation. Superficial phlebitis was the most common complication noted at mid-term follow-up in 5% of cyanoacrylate embolization and 16% of radiofrequency ablation treatments (P < 0.05). One patient in each group had asymptomatic proximal thrombus extension treated with anticoagulation for 2–3 weeks. Three superficial infections from glue clumps were noted in the cyanoacrylate embolization group requiring excision and drainage. Five patients in the radiofrequency ablation group had persistent numbness and one wound complications at the access site. Conclusion Cyanoacrylate embolization offers equivalent success rates with lower mid-term complication rates as radiofrequency ablation.

Sign in / Sign up

Export Citation Format

Share Document